A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome

NCT07695298 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Presumed Ocular Histoplasmosis

Interventions

DRUG: Faricimab Injection [Vabysmo]

Sponsor

Cincinnati Eye Institute, Southwest Ohio

Collaborators

[object Object]